초록 ▼

An augmented ceramic composite including aluminosilicate nanotubes may be added to a biocompatible polymer matrix. Aluminosilicate nanotubes have a surprisingly high biocompatibility, radio opaqueness, and suitability for storing therapeutic compounds for release over time. These surprising advantag

An augmented ceramic composite including aluminosilicate nanotubes may be added to a biocompatible polymer matrix. Aluminosilicate nanotubes have a surprisingly high biocompatibility, radio opaqueness, and suitability for storing therapeutic compounds for release over time. These surprising advantages make aluminosilicate nanotubes, such as halloysite nanotubes, a good candidate for use in various medical applications from bone and dental prosthetics to cancer treatment and prevention. Furthermore, unlike other additives, the addition of certain quantities of halloysite nanotubes increases the strength of the polymer matrix to which it is added.

대표청구항 ▼

1. An augmented ceramic composite, comprising: radiated aluminosilicate nanotubes dispersed in a biocompatible polymer matrix;at least one pharmaceutically effective composition; andwherein the aluminosilicate nanotubes comprise halloysite nanotubes, the biocompatible polymer matrix comprises polyme

1. An augmented ceramic composite, comprising: radiated aluminosilicate nanotubes dispersed in a biocompatible polymer matrix;at least one pharmaceutically effective composition; andwherein the aluminosilicate nanotubes comprise halloysite nanotubes, the biocompatible polymer matrix comprises polymethylmethacrylate (PMMA), and the halloysite nanotubes are disaggregated and dispersed in the PMMA to form an implantable body selected from a group consisting of a bone cement and a dental composite. 2. The augmented ceramic composite of claim 1, wherein the halloysite nanotubes have a length of about 300 to about 2000 nanometers and a diameter of about 10 to about 300 nanometers. 3. The augmented ceramic composite of claim 2, wherein the nanotubes have the length of about 500 to about 1500 nanometers and the diameter of about 30 to about 100 nanometers. 4. The augmented ceramic composite of claim 1, the implantable body having a maximum force displacement greater than a second body would have had if the second body comprised PMMA with the at least one pharmaceutically effective composition but without halloysite nanotubes. 5. The augmented ceramic composite of claim 2, wherein said halloysite nanotubes are provided at a weight percentage of about 0.005 to about 20.0 percent. 6. The augmented ceramic composite of claim 5, wherein said halloysite nanotubes are provided at a weight percentage of about 2 to about 15 percent. 7. An augmented ceramic composite, comprising: radiated aluminosilicate nanotubes dispersed in a biocompatible polymer matrix;wherein the aluminosilicate nanotubes comprise halloysite nanotubes; andthe halloysite nanotubes, the polymer matrix, and at least one pharmaceutically effective composition form an implantable body. 8. The augmented ceramic composite of claim 1, wherein hollow spaces in said halloysite nanotubes comprise the at least one pharmaceutically effective composition selected from a group consisting of antibiotics, anti-inflammatories, bone growth promoting agents, imaging agents, and other chemotherapeutic agents, and any mixtures thereof. 9. The augmented ceramic composite of claim 8, wherein between about 10% to about 40% of the void volume of the nanotubes are filled with the pharmaceutically effective composition. 10. The augmented ceramic composite of claim 1, wherein said halloysite nanotubes are not loaded and the polymethylmethacrylate matrix comprises the at least one pharmaceutically effective composition selected from a group consisting of antibiotics, anti-inflammatories, bone growth promoting agents, imaging agents, and other chemotherapeutic agents, and any mixtures thereof. 11. A method of preparing and/or implanting a biocompatible augmented ceramic composite, comprising: sterilizing halloysite nanotubes with at least radiation; mixing said halloysite nanotubes in a methylmethacrylate monomer; disaggregating said halloysite nanotubes; adding polymethylmethacrylate polymer to the halloysite nanotube-methylmethacrylate monomer mixture; and vacuum mixing. 12. A bone cement or dental composite, comprising: an implantable body comprising a biocompatible augmented ceramic composite comprising radiated halloysite nanotubes dispersed in a polymer of polymethylmethacrylate dissolved in a reactive monomer of methylmethacrylate. 13. The augmented ceramic composite of claim 1, wherein the halloysite nanotubes comprise sterilized halloysite nanotubes. 14. The method of claim 11, further comprising the step of providing bone growth promoting agents and wherein the augmented ceramic composite comprises bone growth promoting agents. 15. The method of claim 11, further comprising the step of providing a pharmaceutically effective composition selected from a group consisting of antibiotics, anti-inflammatories, bone growth promoting agents, imaging agents, and other chemotherapeutic agents, and any mixtures thereof; and wherein the augmented ceramic composite comprises the pharmaceutically effective composition. 16. The bone cement or dental composite of claim 12, wherein the halloysite nanotubes comprise sterilized halloysite nanotubes. 17. The bone cement or dental composite of claim 12, further comprising a pharmaceutically effective composition selected from a group consisting of antibiotics, anti-inflammatories, bone growth promoting agents, imaging agents, and other chemotherapeutic agents, and any mixtures thereof; and the implantable body having a maximum force displacement greater than a second body would have had if the second body comprised PMMA with the pharmaceutically effective composition but without halloysite nanotubes. 18. The method of claim 15, further comprising the step of: implanting the biocompatible augmented ceramic composite; andwherein the composite has a maximum force displacement greater than a second composite would have had if the second composite comprised PMMA with the pharmaceutically effective composition but without halloysite nanotubes. 19. The augmented ceramic composite of claim 7, wherein the at least one pharmaceutically effective composition is selected from a group consisting of antibiotics, anti-inflammatories, bone growth promoting agents, imaging agents, and other chemotherapeutic agents, and any mixtures thereof. 20. The augmented ceramic composite of claim 7, wherein the implantable body is bone cement.